Inferra AI / Company / STE
Steris
STE · Health Care
Last earnings Aug 5, 2026 · Next earnings Nov 4, 2026
Key results
Total revenuequarter
9%
Total revenue from continuing operations for the first quarter of fiscal 2026 increased 9% to $1.4 billion compared with $1.3 billion in the first quarter of fiscal 2025.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Revenuequarter
8%
Constant currency organic revenue growth from continuing operations for the first quarter was 8%.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Net incomequarter
$177.4 million
Total Company First Quarter Results from Continuing Operations As reported, net income from continuing operations for the first quarter was $177.4 million or $1.79 per diluted share, compared with $139.8 million or $1.41 per diluted share in the first quarter of fiscal 2025.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Adjusted net incomequarter
$231.2 million
Adjusted net income for the first quarter of fiscal 2026 was $231.2 million or $2.34 per diluted share, compared with the previous year s first quarter of $201.7 million or $2.03 per diluted share.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Continuing Operations Healthcare revenuequarter
8%
First Quarter Segment Results from Continuing Operations Healthcare revenue as reported grew 8% in the first quarter to $974.7 million compared with $901.2 million in the first quarter of fiscal 2025.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
This performance reflected 13% improvement in service revenue, 6% growth in capital equipment revenue and 5% growth in consumable revenue.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Constant currency organic revenue growth was 8% compared to last year s first quarter.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Healthcare operating incomequarter
$235.5 million
Healthcare operating income was $235.5 million compared with $216.9 million in last year s first quarter.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
AI analysis
Q1 FY2026 · reported Aug 6, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q1 FY2026 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | 9% | — | — |
| Revenue | 8% | — | — |
| Net income | $177.4 million | — | — |
| Adjusted net income | $231.2 million | — | — |
| Continuing Operations Healthcare revenue | 8% | — | — |
| Healthcare operating income | $235.5 million | — | $216.9 million |
Guidance · company-stated
Direction: Raised
“htm EX-99.1 Document Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 First Quarter Total revenue from continuing operations increased 9% constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79 adjusted EPS increased to $2.34 Fiscal 2026 outlook updated DUBLIN, IRELAND - (August 6, 2025) - STERIS plc (NYSE STE) ( STERIS or the Company ) today announced financial results for its fiscal 2026 first quarter ended June 30, 2025.”
“Fiscal 2026 Outlook Updated For fiscal 2026, the Company now expects as reported revenue from continuing operations to increase 8-9% compared with prior expectations of 6-7%.”
“Included in this outlook is the negative impact of tariffs, estimated to reduce pre-tax profit by approximately $45 million, compared with prior expectations of $30 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Capital expenditures are anticipated to be approximately $375 million.
Event summary
First Quarter Segment Results from Continuing Operations Healthcare revenue as reported grew 8% in the first quarter to $974.7 million compared with $901.2 million in the first quarter of fiscal 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “htm EX-99.1 Document Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 First Quarter Total revenue from continuing operations increased 9% constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79 adjusted EPS increased to $2.34 Fiscal 2026 outlook updated DUBLIN, IRELAND - (August 6, 2025) - STERIS plc (NYSE STE) ( STERIS or the Company ) today announced financial results for its fiscal 2026 first quarter ended June 30, 2025.”
Revenue: “Fiscal 2026 Outlook Updated For fiscal 2026, the Company now expects as reported revenue from continuing operations to increase 8-9% compared with prior expectations of 6-7%.”
Company outlook: “Included in this outlook is the negative impact of tariffs, estimated to reduce pre-tax profit by approximately $45 million, compared with prior expectations of $30 million.”
Revenue — Raised (“increased”)
“htm EX-99.1 Document Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 First Quarter Total revenue from continuing operations increased 9% constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79 adjusted EPS increased to $2.34 Fiscal 2026 outlook updated DUBLIN, IRELAND - (August 6, 2025) - STERIS plc (NYSE STE) ( STERIS or the Company ) today announced financial results for its fiscal 2026 first quarter ended June 30, 2025.”
Revenue — Raised (“increase”)
“Fiscal 2026 Outlook Updated For fiscal 2026, the Company now expects as reported revenue from continuing operations to increase 8-9% compared with prior expectations of 6-7%.”
Company outlook — Lowered (“reduce”)
“Included in this outlook is the negative impact of tariffs, estimated to reduce pre-tax profit by approximately $45 million, compared with prior expectations of $30 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Capital expenditures are anticipated to be approximately $375 million.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
STERIS believes that free cash flow is a useful measure of the Company s ability to fund future principal debt repayments and growth outside of core operations, pay cash dividends, and repurchase ordinary shares.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The Company uses free cash flow as a measure to gauge its ability to pay cash dividends, fund growth outside of core operations, fund future debt principal repayments, and repurchase shares.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
, as administrative agent (the Revolving Credit Agreement ) providing for a $ 1,100.0 million revolving credit facility (the Revolving Credit Facility ), which replaced a prior credit agreement, dated as of March 19, 2021.
SEC original ↗Steris — 10-Q Quarterly report10-QAug 7, 2026
Strategy & priorities
The Restructuring Plan includes a strategic shift in our approach to the Healthcare surgical business in Europe, as well as other actions including the impairment of an internally developed X-ray accelerator, product rationalizations and facility consolidations.
SEC original ↗Steris — 10-Q Quarterly report10-QAug 7, 2026
Further, the Company may incur material defense costs as a result of such proceedings, which may also divert management attention from other priorities.
SEC original ↗Steris — 10-Q Quarterly report10-QAug 7, 2026
Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites.
SEC original ↗Steris — 10-Q Quarterly report10-QAug 7, 2026
Our Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing.
SEC original ↗Steris — 10-Q Quarterly report10-QAug 7, 2026
Risks & headwinds
Our performance exceeded expectations and margins improved nicely, despite tariff headwinds.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The increase in operating income was primarily due to improved volume, price, productivity and the benefit of prior restructuring efforts, which was partially offset by tariffs and inflation.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Adjusted earnings per diluted share from continuing operations is also unchanged in the range of $9.90 to $10.15, as favorable foreign currency changes will be offset by increased tariffs and higher employee healthcare benefit costs.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Included in this outlook is the negative impact of tariffs, estimated to reduce pre-tax profit by approximately $45 million, compared with prior expectations of $30 million.
SEC original ↗Steris — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Legal Proceedings 41 Item 1A.
SEC original ↗Steris — 10-Q Quarterly report10-QAug 7, 2026
COMMITMENTS AND CONTINGENCIES We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate.
SEC original ↗Steris — 10-Q Quarterly report10-QAug 7, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q3 2026
- 8-KSTE
Oct 13, 2026
- Q2 2026
- 10-QSTE
Aug 7, 2026
- 8-KSTE
Aug 6, 2026
- 8-K/ASTE
Aug 6, 2026
- 8-KSTE
Aug 5, 2026
- Q1 2026
- 10-KSTE
May 29, 2026
- 8-KSTE
May 11, 2026
- 8-KSTE
May 7, 2026
- 8-KSTE
Apr 6, 2026
- Q4 2025
- 10-QSTE
Feb 6, 2026
- 8-KSTE
Feb 4, 2026
- Q3 2025
- 10-QSTE
Nov 6, 2025
- 8-KSTE
Nov 5, 2025
- Q2 2025
- 10-QSTE
Aug 7, 2025
- 8-KSTE
Aug 6, 2025
- EX-99STE
Aug 6, 2025
- 8-KSTE
Jul 3, 2025
- Q1 2025
- 10-KSTE
May 29, 2025
- 8-KSTE
May 14, 2025
- Q4 2024
- 8-KSTE
Mar 3, 2025
- 10-QSTE
Feb 7, 2025
- 8-KSTE
Feb 5, 2025
- Q3 2024
- 10-QSTE
Nov 7, 2024
- 8-KSTE
Nov 6, 2024
- 8-KSTE
Oct 7, 2024
- Q2 2024
- 10-QSTE
Aug 8, 2024
- 8-KSTE
Aug 6, 2024
- 8-KSTE
Aug 1, 2024
- Q1 2024
- 8-KSTE
May 31, 2024
- 10-KSTE
May 29, 2024
- 8-KSTE
May 8, 2024
Earnings releases
10 documentsPresentations
0 documentsNo presentations for Steris are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Steris are held in this edition of the library.
Mentioned by
2 companiesOther tracked companies whose held documents mention Steris by name or ticker. A mention is counted once per document, from the document text the library holds.
“er 1, 2026 Algoma Steel Group Inc. Provides Guidance for the Third Quarter 2026 SAULT STE. MARIE, Ontario, October 1, 2026 - Algoma Steel Group Inc. (NASDAQ:… …compensation related to the Company’s Omnibus Long Term Incentive Plan, certain invent”
Protagonist Therapeutics, Inc. (PTGX)
“ased to $2.03 • Fiscal 2025 outlook reiterated DUBLIN, IRELAND - (August 6, 2024) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”)… …divestiture related transaction costs and gains or losses, integration costs related to acquisitions, tax r”
See also the earnings calendar for every tracked company’s next earnings date.